The flow cytometric analysis of total p53 protein content and proliferation indices in colorectal cancer, in relation to clinical outcome
The flow cytometric analysis of total p53 protein content and proliferation indices in colorectal cancer, in relation to clinical outcome
This study was undertaken to assess the value of how cytometric measurements of total p53 protein content and proliferation indices derived from in vivo halogenated pyrimidine labelling. Two series of colorectal cancer specimens were studied for which clinical outcome data were recorded. A series of 84 archival, ethanol-fixed, bromodeoxyuridine (BrdUrd) labelled colorectal tumours were analysed by flow cytometry for their total and cell cycle phase p53 protein content using the pAb1801 monoclonal antibody. A second series of 33 freshly obtained tumours was used for assay evaluation and for comparison with the archival material. In the archival series (n = 84), the median p53-pAb1801 LI was 81.9% (range: 11.1-99.8%). In only three tumours could significant amounts of p53 protein not be detected. The median phase specific p53-pAb1801 LI in G0/G1 was 71.6%, in S was 95.5%, and in G2/M was 98.5%. In the series of fresh tumours (n = 33), the median p53-pAb1801 labelling index (LI) was 94.6% (range: 17.9-99.9%). Only two tumours failed to express significant amounts of p53 protein. There was no significant difference in the generally high levels of p53 protein content between the fresh and archival series. Life-table analysis of the patients in the archival series failed to demonstrate a statistical difference in life expectancy in relation to Dukes' stage when rumours were stratified by the median total p53 labelling index. In this study, p53 content and proliferative indices measured by how cytometry do not have independent predictive value over Dukes' grading in determining the outcome of colorectal cancer. Flow cytometry is confirmed as a practical tool for multi-parametric and cell cycle analysis of oncoprotein expression in human tumour biopsies.
Colorectal cancer, Flow cytometry, p53, Proliferation indices
508-515
Rew, D. A.
36dcc3ad-2379-4b61-a468-5c623d796887
Karkera, R.
95de3798-92b7-4c23-83b2-c7fcf25554ff
Mullee, M. A.
fd3f91c3-5e95-4f56-8d73-260824eeb362
Julious, S. A.
e70c3d71-b62d-41a8-8e98-df954f127935
Wilson, George D.
eb5f854f-2cf6-4f0e-b737-b049c44dd16e
October 1996
Rew, D. A.
36dcc3ad-2379-4b61-a468-5c623d796887
Karkera, R.
95de3798-92b7-4c23-83b2-c7fcf25554ff
Mullee, M. A.
fd3f91c3-5e95-4f56-8d73-260824eeb362
Julious, S. A.
e70c3d71-b62d-41a8-8e98-df954f127935
Wilson, George D.
eb5f854f-2cf6-4f0e-b737-b049c44dd16e
Rew, D. A., Karkera, R., Mullee, M. A., Julious, S. A. and Wilson, George D.
(1996)
The flow cytometric analysis of total p53 protein content and proliferation indices in colorectal cancer, in relation to clinical outcome.
European Journal of Surgical Oncology, 22 (5), .
(doi:10.1016/S0748-7983(96)93027-9).
Abstract
This study was undertaken to assess the value of how cytometric measurements of total p53 protein content and proliferation indices derived from in vivo halogenated pyrimidine labelling. Two series of colorectal cancer specimens were studied for which clinical outcome data were recorded. A series of 84 archival, ethanol-fixed, bromodeoxyuridine (BrdUrd) labelled colorectal tumours were analysed by flow cytometry for their total and cell cycle phase p53 protein content using the pAb1801 monoclonal antibody. A second series of 33 freshly obtained tumours was used for assay evaluation and for comparison with the archival material. In the archival series (n = 84), the median p53-pAb1801 LI was 81.9% (range: 11.1-99.8%). In only three tumours could significant amounts of p53 protein not be detected. The median phase specific p53-pAb1801 LI in G0/G1 was 71.6%, in S was 95.5%, and in G2/M was 98.5%. In the series of fresh tumours (n = 33), the median p53-pAb1801 labelling index (LI) was 94.6% (range: 17.9-99.9%). Only two tumours failed to express significant amounts of p53 protein. There was no significant difference in the generally high levels of p53 protein content between the fresh and archival series. Life-table analysis of the patients in the archival series failed to demonstrate a statistical difference in life expectancy in relation to Dukes' stage when rumours were stratified by the median total p53 labelling index. In this study, p53 content and proliferative indices measured by how cytometry do not have independent predictive value over Dukes' grading in determining the outcome of colorectal cancer. Flow cytometry is confirmed as a practical tool for multi-parametric and cell cycle analysis of oncoprotein expression in human tumour biopsies.
This record has no associated files available for download.
More information
Published date: October 1996
Additional Information:
Funding Information:
Financial support was generously provided by the Wessex Medical Trust and by the Cancer Research Campaign. Dr J. V. Watson (Cambridge) kindly provided additional technical advice and support.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
Keywords:
Colorectal cancer, Flow cytometry, p53, Proliferation indices
Identifiers
Local EPrints ID: 447216
URI: http://eprints.soton.ac.uk/id/eprint/447216
ISSN: 0748-7983
PURE UUID: bb1aee77-dba0-49a0-bc53-245f3101e479
Catalogue record
Date deposited: 05 Mar 2021 17:30
Last modified: 18 Mar 2024 03:52
Export record
Altmetrics
Contributors
Author:
R. Karkera
Author:
S. A. Julious
Author:
George D. Wilson
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics